I think you are confusing different product lines from Mesoblast.
REXLEMESTROCEL-L is the new generation product for CHF and CLBP. It’s not the one which was submitted for approval last week for aGVHD.
Please do some more research as you’re making big mistakes by confusing the two.
Ann: FDA Grants RMAT Designation for Rexlemestrocel-L in CLBP, page-58
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.015(1.04%) |
Mkt cap ! $1.661B | |||
| Open | High | Low | Value | Volume |
| $1.44 | $1.46 | $1.40 | $3.815M | 2.664M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11031 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 14844 | 2 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |